Valuation : Appili Therapeutics Inc.

Market Cap 1.32M 961K 826K 777K 709K 91.09M 1.33M 9.21M 3.56M 46.56M 3.61M 3.53M 148M P/E 2025
-1.62x
P/E 2026 -0.44x
Enterprise Value 14.22M 10.32M 8.88M 8.35M 7.62M 979M 14.29M 98.93M 38.28M 500M 38.76M 37.92M 1.59B EV / Sales 2025
152,429,607x
EV / Sales 2026 60,946,081x
Free-Float
99.94%
Yield 2025 *
-
Yield 2026 -
08-15 Appili Therapeutics Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026 CI
07-04 Appili Therapeutics Inc. Receives Notice of Termination for Convenience from National Institute of Allergy and Infectious Diseases on Contract for VXV-01 Program CI
06-27 Appili Therapeutics Inc. Reports Earnings Results for the Full Year Ended March 31, 2026 CI
06-27 Appili Therapeutics Inc. Auditor Raises 'Going Concern' Doubt CI
02-18 Appili Therapeutics announces closing of second tranche of non-brokered private placement RE
02-13 Appili Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2025 CI
12-18 Appili Therapeutics closes first tranche of non-brokered private placement RE
12-15 The Lundquist Institute and Vitalex Biosciences Announces Strategic Advancement of Second-Generation fungal Vaccine VXV-01 through Phase 1 Trials under $40 Million Competitive Contract from NIH/NIAID CI
11-14 Appili Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025 CI
11-14 Appili Therapeutics Brief: On LIKMEZ (ATI-1501), Says "Building Commercial Momentum in the U.S. Through Re-Launch and Increasing Sales Growth" MT
11-14 Appili Therapeutics Brief: Citing New NIAID Non-Dilutive Funding Award of Up to US $40 Million with US$90 Million in Pending Proposals Across Multiple Infectious Disease Programs MT
11-14 Appili Therapeutics Brief: Reported a Q2 Net and Comprehensive Loss of $1.0 million ($0.01 per share) MT
11-05 Appili Therapeutics Announces $750,000 Private Placement for Working Capital, Drug Development MT
1 day-33.33%
1 week-33.33%
Current month-33.33%
3 months-33.33%
6 months-50.00%
Current year-60.00%
1 month 0.01
Extreme 0.01
0.02
Current year 0.01
Extreme 0.01
0.02
1 year 0.01
Extreme 0.01
0.04
3 years 0.01
Extreme 0.01
0.08
5 years 0.01
Extreme 0.01
1.14
10 years 0.01
Extreme 0.01
1.89
Manager TitleAgeSince
Chief Executive Officer 65 01/11/2022
Director of Finance/CFO 68 16/11/2021
Corporate Officer/Principal - 01/10/2022
Director TitleAgeSince
Chairman 50 07/05/2015
Director/Board Member 58 01/10/2018
Chairman 59 13/11/2022
Date Insider Type Main position Quantity % Market Cap. Importance
01/07/26 Option

Chief Executive Officer

75,000 0.0584%
01/07/26 Option

Chief Financial Officer

100,000 0.0779%
01/07/26 Option

Director

100,000 0.0779%
Change 5-day change 1-year change 3-year change Capi.($)
-33.33%-33.33%-33.33%-81.82% 961K
+2.02%+1.26%+41.37%+105.18% 69.19B
-0.62%-4.40%+31.89%+75.11% 62.97B
+1.09%+0.87%-13.22%+382.02% 27.27B
-0.58%-5.60%-4.01%-16.91% 24.78B
-0.93%-0.81%+29.69%+14.38% 25.8B
-0.79%-0.78%+22.68%-16.74% 20.11B
+6.04%+7.25%+233.25%+383.12% 18.47B
-1.43%-2.43%-8.12%+515.88% 14.88B
-0.44%-1.58%+50.48%+161.96% 14.29B
Average -2.89%+0.66%+35.07%+152.22% 27.78B
Weighted average by Cap. +0.59%+0.11%+37.95%+140.79%

Financials

2025 2026
Net sales 0.1 0.07 0.06 0.06 0.05 6.91 0.1 0.7 0.27 3.53 0.27 0.27 11.24 0.24 0.18 0.15 0.14 0.13 16.8 0.25 1.7 0.66 8.59 0.67 0.65 27.33
Net income -2.62M -1.91M -1.64M -1.54M -1.41M -181M -2.64M -18.26M -7.06M -92.32M -7.15M -7M -294M -4.24M -3.08M -2.65M -2.49M -2.27M -292M -4.26M -29.5M -11.41M -149M -11.56M -11.31M -475M
Net Debt 11.07M 8.03M 6.91M 6.5M 5.93M 762M 11.12M 76.99M 29.79M 389M 30.16M 29.51M 1.24B 12.9M 9.36M 8.05M 7.57M 6.91M 888M 12.96M 89.72M 34.71M 454M 35.15M 34.39M 1.44B
Logo Appili Therapeutics Inc.
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company focused on drug development for infectious diseases and medical countermeasures. The Company is advancing a diverse range of anti-infectives, including an FDA-approved ready-made suspension of metronidazole for the treatment of antimicrobial-resistant infections, a vaccine candidate to eliminate a serious biological weapon threat, and a topical antiparasitic for the treatment of a disfiguring disease. Its anti-infective product development portfolio includes three programs: LIKMEZ (ATI-1501), ATI-1701, and ATI-1801. ATI-1501 is its advanced commercial stage asset, a liquid oral taste-masked reformulation of the antibiotic metronidazole. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin.
Employees
7
Date Price Change Volume
02/09/26 CA$0.0100 -33.33% 2,000
01/09/26 CA$0.0150 0.00% 1,000
  1. Stock Market
  2. Stocks
  3. APLI Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!